PL BioScience Appoints Oliver Dick as CTO Amid Global Expansion

PL BioScience GmbH, a leading German life science company, has announced the appointment of Oliver Dick, PhD, as Chief Technology Officer. With over 30 years of experience in life science, diagnostics, and biopharmaceuticals, Dick is poised to enhance the company's operational strategies and support its global growth. Based in Aachen, Germany, PL BioScience is recognized for its innovative Human Platelet Lysate (HPL) products, which are animal-free cell culture solutions.

Dr. Hatim Hemeda, CEO of PL BioScience, highlighted Dick's proven expertise in operational excellence and his ability to drive international expansion. Dick previously held leadership roles at global biotech firms, focusing on process optimization and digital transformation. At PL BioScience, he will spearhead efforts to meet the rising demand for animal-free cell culture supplements worldwide.

This strategic appointment underscores PL BioScience's commitment to pioneering sustainable and ethical laboratory practices in the rapidly evolving field of regenerative medicine.